David W. Nassif - 08 Dec 2021 Form 4 Insider Report for Sio Gene Therapies Inc.

Role: Chief Financial Officer
Signature: David Nassif
Issuer symbol: N/A
Transactions as of: 08 Dec 2021
Net transactions value: -$8,937
Form type: 4
Filing time: 09 Dec 2021, 17:31:32 UTC
Next filing: 10 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SIOX	Common Stock	Award	$0	+17,534	+52%	$0.000000	51,538	08 Dec 2021	Direct
transaction	SIOX	Common Stock	Tax liability	$8,937	-6,294	-12%	$1.42	45,244	08 Dec 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SIOX	Restricted Stock Units	Disposed to Issuer	$0	-17,534	-33%	$0.000000	35,066	08 Dec 2021	Common Stock	17,534		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were sold on behalf of the Reporting Person in the open market to cover withholding taxes relating to the settlement of the vested restricted stock units.
F2	Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on April 15, 2021 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted.
F3	50% of the shares of common stock underlying the remaining restricted stock units vest on April 15, 2022 and the remainder vest on April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date.